Aktis Oncology (NASDAQ:AKTS) Stock Price Up 8.8% – What’s Next?

Shares of Aktis Oncology (NASDAQ:AKTS) traded up 8.8% during mid-day trading on Tuesday . The company traded as high as $33.15 and last traded at $32.7560. Approximately 134,837 shares changed hands during trading, a decline of 58% from the average session volume of 322,742 shares. The stock had previously closed at $30.11.

Analyst Ratings Changes

Several research firms have recently commented on AKTS. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair assumed coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Raymond James Financial started coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective on the stock. Finally, HC Wainwright lifted their target price on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Trading Up 1.0%

The business’s 50-day moving average price is $21.57.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million for the quarter. On average, equities research analysts forecast that Aktis Oncology will post -1.62 EPS for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.